Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/94441
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Godman, Brian | - |
dc.contributor.author | Tubic, Biljana | - |
dc.contributor.author | Allocati, Eleonora | - |
dc.contributor.author | Wladysiuk, Magdalene | - |
dc.contributor.author | McTaggart, Stuart | - |
dc.contributor.author | Kurdi, Amanj | - |
dc.contributor.author | Haque, Mainul | - |
dc.contributor.author | MacBride-Stewart, Sean | - |
dc.contributor.author | Kalemeera, Francis | - |
dc.contributor.author | Massele, Amos | - |
dc.contributor.author | Hoxha, Iris | - |
dc.contributor.author | Markovic Pekovic, Vanda | - |
dc.contributor.author | Petrova, Guenka | - |
dc.contributor.author | Tachkov, Konstantin | - |
dc.contributor.author | Laius, Ott | - |
dc.contributor.author | Harsanyi, András | - |
dc.contributor.author | Inotai, András | - |
dc.contributor.author | Jakupi, Arianit | - |
dc.contributor.author | Henkuzens, Svens | - |
dc.contributor.author | Garuolienė, Kristina | - |
dc.contributor.author | Vella Bonanno, Patricia | - |
dc.contributor.author | Rutkowski, Jakub | - |
dc.contributor.author | Mardare, Ileana | - |
dc.contributor.author | Fürst, Jurij | - |
dc.contributor.author | Pontes, Caridad | - |
dc.contributor.author | Zara, Corinne | - |
dc.contributor.author | Pedrola, Marta Turu | - |
dc.contributor.author | Akter, Farhana | - |
dc.contributor.author | Kwon, Hye-Young | - |
dc.contributor.author | Martin, Antony P. | - |
dc.contributor.author | Banzi, Rita | - |
dc.contributor.author | Wale, Janney | - |
dc.contributor.author | Gulbinovič, Jolanta | - |
dc.date.accessioned | 2022-04-26T14:32:30Z | - |
dc.date.available | 2022-04-26T14:32:30Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Godman, B., Tubic, B., Allocati, E., Wladysiuk, M., McTaggart, S., Kurdi, A., ... & Gulbinovič, J. (2022). Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues. Journal of Applied Pharmaceutical Science, 12(3), 55-72. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/94441 | - |
dc.description.abstract | Sales of medicines continue to grow world-wide driven in part by increasing expenditures on biological medicines leading to concerns with the long-term sustainability of European healthcare systems. The increasing use of biosimilars at lower costs can potentially address this. However, there can be concerns with their prescribing. There are also concerns with biosimilar insulin glargine including concerns with different devices despite increasing sales of longacting insulin analogues worldwide. Consequently, a need to appraise the European biosimilar market incorporating measures to enhance their use including potential ways to increase the prescribing of biosimilars of insulin glargine at lower costs. Multiple approaches were used to undertake the study including researching measures to enhance biosimilar use and their impact across Europe. In addition, undertake cross national research on the utilization and expenditure of long-acting insulin analogues, which includes biosimilars, principally among Central and Eastern European countries. Multiple demand-side measures across the countries have enhanced the use of biosimilars. There was variable use of biosimilar insulin glargine 100 IU/ml driven by increasing use of patented 300 IU/ml formulations and small price differences between the originator and biosimilars in practice. Overall, multiple demand-side initiatives can appreciably increase biosimilar use benefiting all groups. Additional measures are needed to enhance future prescribing of long-acting biosimilar insulin analogues. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Open Science Publishers LLP | en_GB |
dc.rights | info:eu-repo/semantics/openAccess | en_GB |
dc.subject | Drug accessibility -- Law and legislation -- Europe | en_GB |
dc.subject | Biosimilar pharmaceuticals -- Europe | en_GB |
dc.subject | Insulin -- Costs | en_GB |
dc.subject | Drug monitoring -- Europe | en_GB |
dc.subject | Drugs -- Prescribing -- Economic aspects | en_GB |
dc.title | Biosimilars are essential for sustainable healthcare systems ; however, key challenges remain as seen with long-acting insulin analogues | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.7324/JAPS.2022.120306 | - |
dc.publication.title | Journal of Applied Pharmaceutical Science | en_GB |
Appears in Collections: | Scholarly Works - FacHScHSM |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Biosimilars_are_essential_for_sustainable_healthcare_systems_however_key_challenges_remain_as_seen_with_long_acting_insulin_analogues(2022).pdf | 1.09 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.